Luz Garcia
Acute Care · El Paso, TXNPI 1922729839
Payments from drug & device makers
Across 150 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$432
- Merck$424
- Novartis$343
- AstraZeneca$327
- E.r. Squibb & Sons, L.L.C.$265
- Scpharmaceuticals Inc.$192
- plus $590 from 12 others
What the payments were for
- Food & beverage$2,573100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 26 | $432 |
| Merck | 21 | $424 |
| Novartis | 30 | $343 |
| AstraZeneca | 16 | $327 |
| E.r. Squibb & Sons, L.L.C. | 14 | $265 |
| Scpharmaceuticals Inc. | 10 | $192 |
| Johnson & Johnson | 6 | $102 |
| Pfizer | 6 | $100 |
| Novo Nordisk | 4 | $98 |
| Lexicon Pharmaceuticals, Inc. | 4 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $53 |
| Bayer | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
How this compares
$2,573 in reported general payments places this provider in the 85th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 291 | $462,254 |
| FarxigaDapagliflozin Propanediol | 158 | $219,947 |
| EliquisApixaban | 112 | $158,373 |
| JardianceEmpagliflozin | 72 | $108,008 |
| XareltoRivaroxaban | 23 | $33,080 |
| BrilintaTicagrelor | 17 | $20,289 |
| Midodrine Hcl | 18 | $2,278 |
| Metoprolol Succinate | 237 | $2,062 |
| Losartan Potassium | 74 | $683 |
| Lisinopril | 63 | $593 |
| Amlodipine Besylate | 90 | $552 |
| Carvedilol | 71 | $477 |
| Hydralazine Hcl | 29 | $462 |
| Spironolactone | 50 | $342 |
| ClopidogrelClopidogrel Bisulfate | 21 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $343 | $462,254291 claims |
| AstraZenecaFarxiga, Brilinta | $327 | $240,236175 claims |
| PfizerEliquis | $100 | $158,373112 claims |
| Boehringer IngelheimJardiance | $432 | $108,00872 claims |
| Johnson & JohnsonXarelto | $102 | $33,08023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,323 acute care providers in Texas.
Other acute care in El Paso
- Laura WilsonEl Paso$32K
- Ahtesham AliEl Paso$14K
- Adriana SanchezEl Paso$11K
- Haydee BirkhimerEl Paso$10K
- Patricia DandEl Paso$9K
- Dora CarcobaEl Paso$8K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Kim HuynhCypress$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.